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        Recent studies demonstrated a novel proinfl  am-
matory subpopulation of IL-17  –   producing T 
helper cells, termed Th17, that are distinct from 
Th1 and Th2. These Th17 cells have been sug-
gested to mediate infl  ammation associated with 
several organ-related autoimmune diseases in-
cluding experimental allergic encephalitis (EAE) 
(  1  –  3  ), collagen-induced arthritis (  4  ), and experi-
mental autoimmune myocarditis (EAM) (  5, 6  ). 
Evidence supporting a new concept in which 
IL-23  –  dependent Th17, and not IL-12  –  depen-
dent Th1, cells are responsible for autoimmune 
infl  ammation came from reports showing that 
IL-12 (p35)  –  defi  cient and IFN-      –  defi  cient mice 
developed normal or even exaggerated auto-
immune infl  ammation, whereas IL-23 (p19)  –  de-
fi  cient and IL-17 –  defi  cient mice were protected. 
Consequently, there has been a strong interest 
in defi  ning eff  ector cytokines produced by the 
pathological Th17 cells and the conditions and 
factors determining development and activity of 
Th17 cells. Besides IL-17A and IL-17F, Th17 
cells have been reported to coexpress the pro-
infl  ammatory cytokines IL-6, TNF-     (  2, 7  ), 
and IL-22 (  8  ). Similar to Th1 and Th2 develop-
ment, the cytokine environment plays a critical 
role in positive and negative regulation of Th17 
development. TGF-    , IL-6, and IL-1 have been 
shown to induce IL-17 production in naive 
CD4  +   T cells (  9  –  12  ), whereas IL-23 turned out 
to be essential for expansion and survival of Th17 
eff  ector memory cells (  11  ). IL-6 plays a key role 
as it inhibits TGF-      –  induced Treg (  9, 13  ) dif-
ferentiation and induces ROR    t (  14  ), a tran-
scription factor specifi  cally required for Th17 
development. In contrast, IL-27 (  15  ) and IL-25 
(  16  ) have been shown to negatively regulate 
Th17 development. 
  Granulocyte macrophage  –  colony stimulating 
factor (GM-CSF) is secreted in response to infl  am-
matory stimuli such as LPS, IL-1, and TNF-     by 
a variety of diff  erent cells, including endothe-
lium, fi  broblasts, muscle cells, and macrophages, 
and by activated T cells (for review see refer-
ence   17  ). It was fi  rst described as a hematopoietic 
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  Granulocyte macrophage  –  colony stimulating factor (GM-CSF) is critically involved in 
development of organ-related autoimmune infl  ammatory diseases including experimental 
allergic encephalitis and collagen-induced arthritis. Roles of GM-CSF in the initiation and 
in the effector phase of the autoimmune response have been proposed. Our study was 
designed to investigate the mechanisms of GM-CSF in autoimmunity using a model of 
autoimmune heart infl  ammatory disease (myocarditis). The pathological sequel after immu-
nization with heart myosin has been shown previously to depend on IL-1, IL-6, IL-23, and 
IL-17. We found that innate GM-CSF was critical for IL-6 and IL-23 responses by dendritic 
cells and generation of pathological Th17 cells in vivo. Moreover, GM-CSF promoted auto-
immunity by enhancing IL-6  –  dependent survival of antigen specifi  c CD4  +   T cells. These 
results suggest a novel role for GM-CSF in promoting generation and maintenance of Th17 
cells by regulation of IL-6 and IL-23 in vivo. 
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As shown in   Fig. 1 C  , myhc      614-629  -specifi  c CD4  +   T cells from 
WT mice proliferated potently, whereas CD4  +   T cells from 
GM-CSF      /      mice failed to proliferate ex vivo. Moreover, 
GM-CSF      /      mice mounted strongly reduced CD4 T helper 
cell  –  dependent IgG antibody responses, whereas myhc      614-629  -
specifi  c IgM antibody level was comparable to WT controls 
(  Fig. 1 D  ). Thus, our results suggest that GM-CSF is critical 
for development of autoimmune myocarditis by promoting 
autoimmune CD4  +   T cell responses. 
cytokine promoting proliferation and diff  erentiation of macro-
phages, granulocytes, and DC from precursors (  18  –  20  ). 
However, GM-CSF      /      mice showed normal development 
of myeloid cells, including macrophages and DC, except a 
defect of alveolar macrophage function resulting in alveolar 
proteinosis (  21  ). In contrast, analysis of GM-CSF      /      mice 
demonstrated an essential role of GM-CSF for development 
of autoimmune infl  ammatory diseases such EAE and collagen-
induced arthritis (  22, 23  ). In addition, anti  –  GM-CSF ther-
apy from time of immunization or from fi  rst signs of clinical 
disease completely prevented or ameliorated autoimmune in-
fl  ammation, respectively (  23, 24  ). It has been proposed that 
GM-CSF promotes T cell proliferation and pathological Th1 
responses indirectly by activation of macrophages, DC, and 
microglia cells in the initiation or the eff  ector phase and possibly 
the generation of chemoattractant gradients for recruitment of 
infl  ammatory cells to the target organ (  23  ). However, the 
precise mechanisms have remained elusive. 
  In this study, we have determined the mechanism of ac-
tion of GM-CSF in development of EAM, an animal model 
of human dilated cardiomyopathy, the most common form of 
cardiomyopathy (    80  –  90% of cases) for which mortality rates 
remain unacceptably high. EAM is induced by immunization 
of susceptible mice with cardiac myosin or a peptide located 
in the head portion of myosin heavy chain      (myhc      614-629  ) 
emulsifi  ed in CFA. Previous reports have demonstrated that the 
cytokines IL-6, IL-1, IL-23, and IL-17 are crucial for develop-
ment of EAM (  5, 25, 26  ), whereas IFN-     is a negative regula-
tor of heart infl  ammation (  27, 28 ). Thus, the cytokine network 
responsible for pathological infl  ammation in the heart (EAM) 
and brain (EAE) appears to be very similar. 
  We found that GM-CSF was essential to inhibit apoptosis 
and promote IL-17 production by autoimmune CD4  +   T cells. 
Both activities are not mutually exclusive and can be medi-
ated by IL-6. In fact, we found that GM-CSF was essential 
for IL-6 and IL-23 production by DC and/or macrophages 
in the initiation phase of the autoimmune response. 
    RESULTS   
  GM-CSF      /      mice are protected 
from autoimmune myocarditis 
  To investigate the role of GM-CSF in autoimmune myocar-
ditis, we immunized GM-CSF      /      mice and BALB/c controls 
with a peptide derived from the myhc (myhc      614-629  ) in CFA 
on day 0 and boosted on day 7. By day 21, WT mice devel-
oped severe cardiac infl  ammatory lesions, characterized by 
infi  ltrates of lymphocytes, histiocytes, and neutrophils. In 
contrast, GM-CSF      /      mice showed strongly reduced disease 
prevalence and histological score because of few infl  ammatory 
foci (  Fig. 1, A and B  ).   The few lesions found in the hearts of 
GM-CSF      /      mice had a similar cellular composition as the 
infl  ammatory infi  ltrates of WT hearts (unpublished data). 
  EAM is a CD4 T cell  –  mediated disease (  29  ). To assess acti-
vation and function of myosin-specifi  c CD4  +   T cells, we puri-
fi  ed splenic CD4  +   T cells from immunized mice and stimulated 
these with myhc      614-629   presented by WT primary DC in vitro. 
    Figure 1.         Reduced autoimmune myocarditis, T cell proliferation, 
and antibody responses to heart myosin in GM-CSF  –  defi  cient mice. 
 GM-CSF    /     (open circles) and WT (closed circles) mice were immunized at 
days 0 and 7 with myhc    614-629   peptide in CFA. Hearts were removed at day 
21 and fi  xed in 4% formalin. (A) The severity of infl  ammatory infi  ltrates 
was scored as described in Materials and methods. (B) Representative im-
ages of hematoxylin and eosin stainings of WT and GM-CSF     /     heart  sec-
tions. Bars: (left) 2 mm; (middle) 0.5 mm; (right) 0.1 mm. (C) CD4  +   T  cells 
were isolated from the spleen 21 d after immunization and in vitro re-
stimulated with BM-DC and titrating amounts of myhc    614-629 .  Prolifera-
tion was assessed by   3  H-thymidine incorporation after 3 d of culture. 
(D) Serum titers of myhc    614-629 -specifi  c IgM and IgG at day 21 d after 
immunization measured by ELISA. Horizontal lines represent the mean titer 
for each group (D) and the median histological scores of groups (A). Data 
shown are representative of three to four experiments. *, P   <   0.05.     JEM VOL. 205, September 29, 2008 
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cantly augmented production of IL-6, IL-12, and TNF-    , 
and transcription of IL-23p19 by CpG stimulated primary 
DC of both WT and GM-CSF      /      mice (  Fig. 2, B and C  ) but 
  GM-CSF enhances secretion of proinfl  ammatory 
cytokines by DC 
  DC are the key cells for priming T cells in vivo (  30  ). It is 
known that diff  erent stages of maturation have diff  erent ef-
fects on immune responses (  31  ). Immature (or semimature) 
DC have been shown to induce T cell anergy or tolerance 
(  32  ), whereas combined toll-like receptor (TLR) and CD40 
stimulation of mature DC can break tolerance and induce 
autoimmune disease (  33  ). 
  Primary DC from spleens of WT and GM-CSF      /      mice 
showed comparable surface expression of the maturation mark-
ers MHC class II, CD40, and CD86 before and after stimula-
tion with CpG or LPS, the ligands for TLR9 and TLR4, 
respectively (  Fig. 2 A  ).   Moreover, production of the proin-
fl  ammatory cytokines IL-6, IL-12, and TNF-     by DC of 
WT and GM-CSF      /      mice was comparably increased upon 
stimulation with CpG (  Fig. 2 B  ) or LPS (not depicted). In 
contrast, WT DC did not produce detectable GM-CSF (un-
published data). Addition of recombinant GM-CSF signifi  -
    Figure 2.         GM-CSF enhances TLR-induced production of proin-
fl  ammatory cytokines by DC.   DC isolated from spleens of naive WT and 
GM-CSF     /     mice were stimulated with 1   μ  M CpG or 1   μ  g/ml LPS in vitro. 
(A) Surface expression of CD86, CD40, and MHC class II was assessed by 
fl  ow cytometry after 6 h. Unstimulated cells (shaded curve), stimulated 
WT (solid line), GM-CSF     /     (dashed line), and GM-CSF     /     DC in the pres-
ence of 20 ng/ml rGM-CSF (dotted line). (B) ELISA measurement of IL-6, 
IL-12(p40/p70), and TNF-     in supernatants of DC stimulated for 24 h with 
CpG in the presence and absence of 20 ng/ml GM-CSF. (C) IL-23p19 mea-
sured by quantitative PCR of DC stimulated for 4 h with 1   μ  M CpG in the 
presence and absence of GM-CSF. One representative experiment of at 
least two is shown. Error bars indicate SD.     
    Figure 3.         Reduced production of IL-6 in immunized GM-CSF      /      
mice.   WT and GM-CSF     /     mice were immunized s.c. with myhc    614-629 /
CFA as described in the   Fig. 1   legend. (A) At the times indicated, CD11b  +  
and CD11c  +   cells were isolated by magnetic sorting and cultured in the 
presence and absence of anti-CD40 for 20 h. IL-6 concentrations in the 
supernatant was measured by ELISA. (B) Expression of IL-6 relative to 
    -actin was assessed by quantitative PCR using cDNA generated from 
CD11b  +   cells. (C) At day 7, CD11c  +   cells were isolated by magnetic sorting 
and cultured in the presence and absence of anti-CD40 for 24 h (4   ×   10  5  
DC per well). IL-6, IL-23, and IL-12p40 levels in the supernatant were 
measured by ELISA. (D) Analysis of draining LN cells by fl  ow cytometry at 
day 4 after immunization. Histograms show expression of CD80, CD86, 
CD40, and MHC class II gated on CD11c  +   cells. Continuous and dotted 
lines represent cells of immunized WT and GM-CSF     /     mice,  respectively. 
Shaded curves represent cells of naive mice. (E) BM-derived DC of WT and 
GM-CSF     /     mice were pulsed with 10   μ  g/ml myhc    614-629   and  stimulated 
with 1   μ  g/ml LPS and 5   μ  g/ml anti-CD40 for 4 h before injection into WT 
and GM-CSF     /     mice at days 0, 2, and 4. At day 10, hearts were removed 
and myocarditis scored by histology. Horizontal lines indicate median. 
Error bars in A indicate SD of triplicate culture wells. Cells were isolated 
from pooled draining LN of three mice per time point. Error bars in C indi-
cate SD of triplicate cultures of draining LN DC of four to fi  ve mice per 
time point. Data shown are representative of at least two experiments. 
*,  P   <   0.05.   2284 GM-CSF PROMOTES IL-6 RESPONSES AND TH17 SURVIVAL   | Sonderegger et al. JEM VOL. 205, September 29, 2008 
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had no eff  ect on up-regulation of MHC class II, CD40, and 
CD86 (  Fig. 2 A  ). These results suggest that GM-CSF produced 
by non-DC can augment production of proinfl  ammatory cyto-
kines by DC during an immune response but that it is not re-
quired for homeostatic DC development or up-regulation of 
classical DC maturation/activation markers. 
  Reduced IL-6 production by DC in GM-CSF      /      mice 
  To assess cytokine production by antigen-presenting cells in 
myhc      614-629  /CFA-immunized WT and GM-CSF      /      mice, 
we purifi  ed a gemisch of cells expressing CD11b and/or CD11c, 
including macrophages and DC (Mac/DC), from spleens at 
various time points after immunization and cultured them in 
the absence or presence of agonist anti-CD40 mAb to mimic 
stimulation by activated T cells through CD40L. As shown in 
  Fig. 3 A  , Mac/DC from WT mice produced IL-6 from day 2 
peaking at day 7 after immunization, which was two- to three-
fold enhanced by CD40 stimulation.   In contrast, IL-6 produc-
tion by Mac/DC from KO was markedly impaired without and 
with CD40 stimulation. IL-6 expression in vivo determined by 
real time PCR was     10-fold reduced in Mac/DC of GM-
CSF      /      mice at day 7 after innoculation (  Fig. 3 B  ). Purifi  -
cation of CD11c  +   cells, including CD11c  +  CD11b        and 
CD11c  +  CD11b  +   DC, were a source of IL-6, IL-23, and IL-12/
23p40 in immunized WT mice. Both IL-6 and IL-23 produc-
tion was impaired in DC from GM-CSF      /      mice (  Fig. 3 C  ). 
To exclude impaired maturation of DC and macrophages in 
GM-CSF      /      mice, we measured expression of typical matura-
tion markers directly ex vivo. We found comparable MHC 
class II, CD80, CD86, and CD40 on cell surface of CD11c  +  DC 
in WT and GM-CSF      /      mice isolated at days 4 (  Fig. 3 D  ) and 7 
(not depicted) after immunization. Similarly, macrophages 
(i.e., CD11b  +  cells) did not show a diff  erence in these surface 
molecules, although their expression was expectedly weaker than 
on DC (unpublished data). Comparable expression of CD40 rules 
out reduced stimulation of Mac/DC from GM-CSF      /      mice 
by agonistic CD40 mAb. These data demonstrate that GM-
CSF is essential for IL-6 and IL-23 production by DC in vivo 
in response to immunization with autoantigen in CFA and con-
fi  rm the data showing that exogenous GM-CSF enhances IL-6 
and IL-23 production by CpG-stimulated DC (  Fig. 2  ). 
  Activated DC induce mild myocarditis in GM-CSF      /      mice 
  We next asked whether LPS/CD40 activation of BM-DC 
grown in the presence of recombinant GM-CSF could re-
store disease in GM-CSF      /      mice. To this end, BM-DC of 
WT and GM-CSF      /      mice were loaded with myhc      614-629   
and activated with LPS and anti-CD40 mAb before adoptive 
transfer into both WT and GM-CSF      /      recipients. As shown 
in   Fig. 3 E  , both WT and GM-CSF      /      DC induced compa-
rably strong heart infl  ammation in WT mice confi  rming the 
ability of TLR/CD40-activated DC to induce myocarditis 
and suggesting that DC of GM-CSF      /      mice have no intrinsic 
defect in proinfl  ammatory cytokine production when grown 
in exogenous GM-CSF. Interestingly, injection of GM-CSF  –
  derived BM-DC activated with LPS/CD40 partially restored 
disease development in GM-CSF      /      mice, although the dis-
ease score was still signifi  cantly reduced compared with WT 
recipient mice (  Fig. 3 E  ). These results show that BM-DC 
grown and activated with a combination of GM-CSF, LPS, 
and CD40 induce mild myocarditis in GM-CSF      /      mice, 
probably by secretion of IL-6 and IL-23 as indicated in   Figs. 2 
(B and C) and 3 (A  –  C)  . In addition, the data indicate that 
such activated DC trigger GM-CSF production by other cells, 
which are key for development of severe myocarditis. 
  T cell proliferation and differentiation of Th17 cells, 
but not Th1 and Th2 cells, is impaired in GM-CSF  –  defi  cient 
CD4 T cells in vitro 
  The results shown in   Fig. 1 C   suggest that GM-CSF is re-
quired for activation, diff  erentiation, expansion, and/or sur-
vival of autoimmune CD4  +   T cells. To experimentally address 
these possibilities, we capitalized from crossing DO11.10 trans-
genic mice expressing OVA  323-339  -specific TCR with GM-
CSF      /      mice. Naive (i.e., CD62L  hi  ) DO11.10 transgenic 
T cells were isolated from GM-CSF      /      and WT mice and 
cultured with both GM-CSF      /      and WT splenic DC in the 
presence of titrated concentrations of specifi  c antigen to mea-
sure T cell activation, proliferation, and Th1/Th2 polarization 
at days 3 and 5, respectively. T cell activation, measured by 
up-regulation of CD25 and down-regulation of CD62L, was 
unaff  ected in the absence of GM-CSF (  Fig. 4 A  ).   In contrast, 
T cell proliferation was impaired in cultures containing GM-
CSF      /      CD4  +   T cells, independent of whether DC were 
derived from GM-CSF      /      or WT mice, and it was reconsti-
tuted by adding recombinant GM-CSF (  Fig. 4 B  ). For un-
known reasons, a commercially available GM-CSF  –  blocking 
antibody failed to inhibit T cell proliferation in this experi-
mental setup. Th1 and Th2 cell diff  erentiation was induced by 
culturing cells with high and low dose antigen, respectively, 
    Figure 4.         GM-CSF production by CD4  +   T cells promotes proliferation and differentiation of Th17, but not Th1 or Th2, cells in vitro.   Naive 
OVA  323-339   TCR transgenic CD4  +   T cells purifi  ed from spleens of DO11.10/GM-CSF     /     or  DO11.10/GM-CSF +/+   mice were cocultured with splenic DC purifi  ed 
from GM-CSF-defi  cient (KO) or WT mice in the presence of indicated concentrations of ovalbumin protein or OVA  323-339   peptide. (A) CD4  +   T cell activation 
measured by CD25 and CD62L surface expression after 3 d of culture. (B) CD4 T cell proliferation measured by pulsing cells with   3  H-Thymidine for the last 
12 h of a 60-h coculture. (C) Th1/Th2 cell differentiation driven by indicated antigen concentrations was determined by intracellular staining of IFN-     and 
IL-4 after 5 d of coculture. (D and E) Cocultures were stimulated by 10   μ  M OVA  323-339   and 1   μ  M CpG for 4 d. IL-17, IFN-    , and GM-CSF production by 
CD4  +   T cells was determined by intracellular staining in cultures containing GM-CSF  +/+   CD4 +   T cells and DC (D) or indicated combinations of WT and KO 
T cells and DC (E). (F) WT and KO CD4  +   T cells and DC were cultured with anti-CD3 in Th17-polarizing conditions including 5 ng/ml TGF    1, 20 ng/ml IL-6, 
20 ng/ml IL-21, 1   μ  M CpG, and 100   μ  g/ml curdlan. Cytokine production was determined by intracellular staining at day 4.     
 2286 GM-CSF PROMOTES IL-6 RESPONSES AND TH17 SURVIVAL   | Sonderegger et al. 
    Figure 5.         GM-CSF prevents apoptosis of specifi  c T cells.   CD4 +   T cells were purifi  ed from DO11.10/GM-CSF  +/+   and  DO11.10/GM-CSF    /   mice  and 
labeled with CFSE before intravenous injection into WT or GM-CSF     /     mice (5   ×   10  6   cells per mouse) at day 3. Mice were immunized s.c. with 200   μ  g JEM VOL. 205, September 29, 2008 
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OVA  323-339   peptide in CFA at day 0. (A) KJ1-26  +   CD4 T cell expansion was monitored over 10 d in the blood of mice (  n   = 4). The frequency of KJ1-26  +   CD4 +  
T cells in control animals immunized with CFA only was   <  0.5%. (B) Total number of KJ1-26  +   cells in draining LN at days 3 and 5 after immunization. Filled 
columns, DO11.10/GM-CSF  +/+ CD4 +  → GM-CSF +/+   mice; open columns, DO11.10/GM-CSF     /     CD4 +  → GM-CSF    /     mice  ( n   = 3). (C) Proliferation of KJ1-26  +  
CD4  +   T cells is shown by CFSE dilution at days 3 (left) and 5 (right). (D) Annexin V (top) and PI (bottom) staining of KJ1-26  +   CD4 +   T cells in draining LN at 
days 3 and day 5. (E) Shown is the number of cell division determined by CFSE dilution and percentage of apoptotic (Annexin V  +   PI     )  KJ1-26 +   cells at day 
3 after immunization. (F) WT and GM-CSF     /     mice were injected with GM-CSF     /    /DO11.10 or GM-CSF  +/+ /DO11.10  CD4 +   T cells before immunization with 
OVA  323-339  /CFA. Shown is the frequency of apoptotic (Annexin V  +   PI     )  KJ1-26 +   cells at day 3 after immunization. Error bars indicate SD of three mice per 
group. One representative experiment of two is shown. * , P   <   0.05; ** , P   <   0.01.     
 
as reported previously (  34  ). A proportion of IFN-      +   (Th1) 
and IL-4  +   (Th2) cells coproduced GM-CSF in WT CD4  +   T 
cells (unpublished data). However, Th1 and Th2 diff  eren-
tiation remained unaff  ected in GM-CSF-defi  cient CD4  +   T 
cells. (  Fig. 4 C  ). 
  Th17 cell diff  erentiation in vitro can be induced by TCR 
stimulation in the presence of TGF-     together with IL-6 
or IL-21 (  9, 11  ). In addition, exposure of DC to microbial 
products, such as CpG and Curdlan, drives Th17 polarization 
by stimulation of IL-6 and other infl  ammatory cytokines 
(i.e., IL-1 and IL-23), which may refl  ect the more physio-
logical situation. To assess the role of GM-CSF in Th17 po-
larization in vitro, we performed four-way cocultures of WT 
or GM-CSF      /      DC with CD4  +   T cells from DO11.10 WT 
or GM-CSF      /      mice and specifi  c antigen in the presence of 
CpG. WT CD4  +   T cells grown in this condition diff  erenti-
ated into populations secreting GM-CSF, IL-17, and/or 
IFN-     (  Fig. 4 D  ). Th17 cell diff  erentiation was impaired in 
cultures containing GM-CSF  –  defi  cient CD4  +   T cells with 
KO or WT DC (  Fig. 4 E  ). Furthermore, DC and CD4  +   
T cells from WT and KO mice were cultured with anti-CD3 
in the presence of cytokines (i.e., IL-6/TGF-     and IL-21/
TGF-    ) or Pathogen associated molecular patterns (PAMPs; 
i.e., CpG and Curdlan) known to promote Th17 diff  erentia-
tion. Confi  rming data obtained in antigen-specifi  c cultures 
shown in   Fig. 4 E  , Th17 polarization induced by CpG and 
Curdlan was dependent on GM-CSF production by CD4  +   
T cells (  Fig. 4 F  ). In contrast, Th17 development induced by 
exogenous IL-6/TGF-     or IL-21/TGF-     was comparable 
in cultures containing GM-CSF  –  defi  cient and WT CD4  +   
T cells (  Fig. 4 F  ), suggesting that exogenous IL-6 (or IL-21) 
overcomes GM-CSF requirement. Notably, DC/CD4 stim-
ulation cultures grown with exogenous GM-CSF together 
with TGF-     in the absence of IL-6 did not induce Th17 dif-
ferentiation (unpublished data), indicating that microbial 
stimulation of the DC is critical. 
  Collectively, these data suggest that DC produce proin-
fl  ammatory cytokines, including IL-6 but not GM-CSF, upon 
microbial stimulation with PAMPs. This promotes GM-CSF 
production by CD4  +   T cells, which acts back on DC to fur-
ther enhance IL-6-production resulting in Th17 diff  erentia-
tion and proliferation. 
  GM-CSF is essential for CD4 T cell survival in vivo 
  To confi  rm the importance of GM-CSF in T cell proliferation 
in vivo, we performed four-way adoptive transfer experiments 
by injection of GM-CSF  –  defi  cient or GM-CSF  –  competent 
OVA  323-339   specifi  c CD4  +   T cells (from DO11.10 mice) into 
GM-CSF      /      and WT mice. CD4  +   T cells were labeled with 
CFSE prior to injection to monitor cell cycling and in vivo 
tracking. Mice were immunized 1 d later with OVA  323-339  /
CFA, and DO11.10 T cells were monitored longitudinally in 
the blood. GM-CSF  –  competent CD4  +   T cells expanded 
considerably in immunized WT hosts until day 7 before they 
started to collapse. Expansion and collapse of GM-CSF  –  defi  -
cient CD4  +   T cells was unaltered in WT hosts. In contrast, 
no such expansion was observed in GM-CSF      /      recipients 
(  Fig. 5 A  ).   Consistently, a signifi  cantly reduced number of 
DO11.10 T cells was observed in draining LN of GM-CSF      /      
compared with WT hosts at days 3 and 5 after immuniza-
tion (  Fig. 5 B  ). 
  To determine whether GM-CSF promoted cell expan-
sion by enhancing the rate of cell division, we measured 
CFSE dilution (  35  ). Surprisingly, we found that cell cycling 
was not dependent on GM-CSF (  Fig. 5 C  ). Therefore, we hy-
pothesized that reduced CD4 T cell numbers in the absence 
of GM-CSF resulted from enhanced cell death. To test this, 
we measured apoptosis and cell death by staining transgenic 
CD4  +   T cells from draining LN with Annexin-V and prop-
idium iodide (PI) after OVA/CFA immunization. Indeed, we 
found threefold- and twofold-increased numbers of Annexin-V 
transgenic T cells in GM-CSF      /      mice at days 3 and 5, respec-
tively (  Fig. 5 D  ). Similarly, PI-positive cells were increased 
in GM-CSF      /      mice at these days (  Fig. 5 D  ). By gating on 
cells that had undergone the same number of cycles as mea-
sured by CFSE dilution, we found that the percentage of 
apoptotic cells (Annexin-V  +   PI       ) increased with the division 
number and that this increase was much stronger in GM-
CSF      /      mice. After fi  ve cell divisions, the number of apop-
totic T cells in GM-CSF      /      mice was threefold higher (  Fig. 
5 E  ). As expected from the results in the previous paragraph 
(  Fig. 5 A  ), apoptosis was increased in GM-CSF      /      recipients 
irrespective of the ability of transferred T cell to produce GM-
CSF or not (  Fig. 5 F  ). These results demonstrate that GM-CSF 
produced by non  –  T cells sustains survival of antigen-specifi  c 
T cells in vivo. 
  GM-CSF sustains IL-6  –  mediated T cell survival 
  It has been reported that GM-CSF receptor is not expressed 
by resting and activated splenic T cells (  36  ). Indeed, using 
sensitive quantitative RT-PCR, we could not detect expres-
sion of GM-CSFR-     and the signal transducing      subunit 2288 GM-CSF PROMOTES IL-6 RESPONSES AND TH17 SURVIVAL   | Sonderegger et al. 
This result suggests that GM-CSF does not act on the expand-
ing T cells directly but mediates T cell survival indirectly, 
possibly by stimulating production of T cell growth/survival 
(AIC2B) by naive or activated CD4  +   T cells diff  erentiated in 
Th1, Th2, or Th17 polarizing conditions (  Fig. 6 A  ).   In con-
trast, primary splenic DC expressed both GM-CSFR subunits. 
    Figure 6.         T cell survival is mediated by DC-secreted factors and IL-6.   (A) Expression of GM-CSFR-   ,  GM-CSFR-    (AIC2B), and IL-2R     was  deter-
mined by quantitative RT-PCR using cDNA of cells indicated. Naive CD62L  +   CD4 +   T cells (lane 1) and splenic CD11c  +   DC (lane 5) were purifi  ed by fl  ow cyto-
metry (purity   >   98%). Th1 (lane 2), Th2 (lane 3), and Th17 (lane 4) polarized CD4  +   T cells. (B and C) DC of GM-CSF     /     or  GM-CSF +/+   mice were cultured 
with purifi  ed CD4  +   T cells from DO11.10/GM-CSF     /     or  DO11.10/GM-CSF +/+   mice, respectively, in the presence of titrating amounts of OVA  323-339  . (B) IL-6 
levels in the culture supernatant at day 3 were determined by ELISA. (C) Proliferation measured by   3  H-Thymidine incorporation in the absence and in the 
presence of 20 ng/ml rIL-6. (D) Splenocytes of DO11.10/GM-CSF  +/+   or  GM-CSF    /     mice were cultured with 1   μ  M OVA  323-339   in the absence and presence of 
20 ng/ml rIL-6 for 3 d before staining of cells with KJ1-26  +   mAb, Annexin V (AV), and PI and analysis by fl  ow cytometry. Dot plot gated on KJ1-26  +   cells 
shows early apoptotic cells (PI      AV +  ), late apoptotic (PI  + AV +  ), and dead cells (PI  +   AV     ).  (E)  GM-CSF – defi  cient cultures were supplemented with rIL-1, rIL-2, 
or rIL-6. Proliferation was measured by   3  H-Thymidine incorporation after 3 d of culture. Proliferation index was calculated as described in Materials and 
methods. (F) CD4  +   T cells purifi  ed from DO11.10/GM-CSF  +/+   or  DO11.10/GM-CSF    /     mice were injected i.v. into GM-CSF  +/+   or  GM-CSF    /     mice,  respec-
tively. 2 d later, groups of KO and WT mice were implanted with osmotic minipumps containing hIL-6 or were sham operated. Subsequently, mice were 
immunized with 200   μ  g OVA  323-339   peptide  emulsifi  ed in CFA. After 7 d, draining LN and spleen cells were analyzed by fl  ow cytometry. Symbols indicate 
total number of splenic KJ1-26  +   cells of individual mice. Horizontal lines indicate averages of groups. Shown is one representative experiment of three 
performed. *,   <   0.05. Error bars indicate SD.     JEM VOL. 205, September 29, 2008 
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purifi  ed CD4  +   T cells from LN of GM-CSF      /      mice at day 8 
(  Fig. 7 B  ). At day 14, however, we found strongly reduced 
numbers of both IL-17- and IFN-      –  producing CD4  +   T cells 
factors in GM-CSF  –  responsive cells such as DC and macro-
phages. We showed that exogenous and endogenous GM-
CSF enhanced IL-6 production by DC and/or macrophages 
(  Fig. 2 B; and Fig. 3, A and B  ). Consistently, we found that 
endogenous GM-CSF was critically required for antigen-de-
pendent IL-6 production in T cell/DC cocultures (  Fig. 6 B  ). 
Neutralization of endogenously produced IL-6 by mAb re-
duced proliferation in WT cocultures, although not to val-
ues seen in GM-CSF  –  defi  cient cultures (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20071119/DC1). 
These data suggest that GM-CSF regulates CD4 T cell ex-
pansion, at least partially, through induction of IL-6. Indeed, 
supplementation of GM-CSF  –  defi  cient cocultures with IL-6 
reconstituted T cell proliferation (  Fig. 6 C  ) and inhibited 
apoptosis (  Fig. 6 D  ), whereas rIL-2 or rIL-1     showed a small 
or no eff  ect, respectively (  Fig. 6 E  ). 
  We next studied whether IL-6 supplementation can re-
store CD4 T cell expansion in GM-CSF  –  defi  cient mice in vivo. 
IL-6 has a fast clearance kinetic in the blood, and periodic 
IL-6 injection is therefore not suitable to compensate contin-
uous endogenous release (unpublished data). To ensure a 
continuous supply, we implanted osmotic minipumps con-
taining IL-6 in mice after injection of naive DO11.10 CD4  +   
T cells. As shown in   Fig. 6 F  , the total number of DO11.10 
CD4  +   T cells was reduced in GM-CSF      /      mice compared 
with WT mice 7 d after immunization. Delivery of IL-6 to 
GM-CSF      /      mice increased the expansion of DO11.10 T 
cells. A similar reconstitution was also seen in the blood and 
LN (unpublished data). Collectively, these data indicate that 
GM-CSF prevents apoptosis and maintains CD4  +   T cell re-
sponses, at least partially, by stimulation of IL-6 production 
in vivo. 
  IL-17  –  producing cells CD4 T cells are reduced 
in GM-CSF      /      mice 
  IL-6 and IL-23 are key factors for development, maintenance, 
and pathogenicity of IL-17  –  producing CD4  +   T (Th17) cells. 
Considering the defect of GM-CSF      /      CD4  +   T cells in produc-
ing IL-17 in vitro, we studied Th17 development in GM-CSF      /      
mice in vivo  .   To this end, we transferred DO11.10/GM-
CSF      /      and DO11.10/GM-CSF  +/+   CD4  +   T cells to KO 
and WT mice, respectively. Immunization with OVA  323-339  /
CFA resulted in a high frequency of IL-17  +  IFN-            (Th17) 
cells and lower frequencies of IFN-      +  IL-17        (Th1) and IL-
17  +  IFN-      +   coproducers among OVA-specifi  c CD4  +   T cells 
in GM-CSF  –  competent mice. Th17 and IL-17  +  IFN-      +   
CD4 populations were strikingly reduced, whereas frequen-
cies of Th1 cells were unaff  ected in GM-CSF      /      mice (  Fig. 
7 B  ).   Thus, GM-CSF was critical for development and sur-
vival of IL-17  –  producing cells upon immunization with an-
tigen in CFA in vivo. 
  Finally, we determined the role of GM-CSF in develop-
ment of IL-17  –  producing CD4  +   T cells in autoimmune 
myocarditis. GM-CSF      /      and control mice were immunized 
at days 0 and 7 with myhca  614-629  /CFA. Real time PCR anal-
ysis showed reduced   il17   but normal   ifng   gene expression in 
    Figure 7.         GM-CSF      /      mice show reduced frequencies of IL-17  +  IFN-             
and IL-17  +  IFN-      +   CD4  +   T cell populations.   (A)  CD4 +   T cells purifi  ed 
from DO11.10/GM-CSF  +/+   or  DO11.10/GM-CSF    /     mice were adoptively 
transferred to GM-CSF  +/+   or  GM-CSF    /     mice, respectively, 2 d prior to 
immunization with 200   μ  g OVA  323-339   peptide  emulsifi  ed in CFA. Mice were 
boosted at day 7 and draining LN were removed at day 14 to determine 
KJ1-26  +   CD4 +   T cells producing IL-17 or IFN-     by  fl  ow cytometry. Top 
shows dot plots of a representative mouse per group. Bottom shows the 
frequency of cytokine-producing cells in individual mice. (B and C) GM-
CSF     /     and  GM-CSF +/+   mice were immunized with myhc    614-629  /CFA at days 
0 and 7. (B) IL-17 and IFN-     expression was determined by real-time PCR 
using cDNA from CD4  +   T cells purifi  ed from draining LN at day 8. Values 
show means of groups (  n   = 3) of mice   ±  SD. (C) At day 14, CD4  +   T cells were 
isolated from LN and restimulated with myhc    614-629   as described in 
Materials and methods. IFN-    –   and  IL-17 – producing  cells  were  determined 
by ELISPOT analysis. Values indicate individual mice and means of groups.    2290 GM-CSF PROMOTES IL-6 RESPONSES AND TH17 SURVIVAL   | Sonderegger et al. 
stimulation. Consistently, we found that stimulation of splenic 
DC from WT and GM-CSF      /      mice with rGM-CSF sub-
stantially increased TLR-induced production of the proin-
fl  ammatory cytokines IL-6, IL-23, and TNF-    . Moreover, 
we showed that IL-6 and IL-23 production by DC was 
strongly impaired in myhc    /CFA-immunized GM-CSF      /      
mice. Both IL-6 and IL-23 are essential for the development 
of EAM (  5, 25  ), EAE (  38  –  41  ), arthritis (  42  –  44  ), and colitis 
(  45  –  48  ), demonstrating the importance of these two cyto-
kines for development of organ-related autoimmune and in-
fl  ammatory diseases. Although some of these studies showed 
reduced CD4 T cell proliferation (  25  ) and IFN-     production 
(  39, 49  ) in the absence of IL-6, it is now thought that IL-6 
mediates autoimmune disease by promoting development of 
pathogenic Th17 cells (  9, 11  ). However, in addition to Th17 
development, IL-6 has been shown to prevent apoptosis of 
eff  ector and memory T cells (  50  ). Similarly, we found that 
reduced expansion of antigen-specifi  c CD4  +   T cells in im-
munized GM-CSF      /      mice was caused by enhanced apopto-
sis and not a defect in T cell activation or cell division rate. 
  It has been shown previously that a soluble factor secreted 
by activated DC was able to restore impaired proliferation of 
CD4  +   T cells from GM-CSF      /      mice in vitro (  51  ). We have 
identifi  ed that this factor is IL-6. Delivery of recombinant 
IL-6 to GM-CSF      /      mice in osmotic minipumps or to APC-
T cell cocultures in vitro restored proliferation by inhibition 
of apoptosis of antigen-specifi  c GM-CSF      /      CD4  +   T cells. It 
should be noted that we failed to reconstitute autoimmune 
myocarditis in GM-CSF      /      mice and recovery of Th17 cells 
was achieved partially with variable results by implantation of 
IL-6  –  secreting osmotic minipumps or by infection with re-
combinant adenovirus expressing IL-6 (mAd5-IL6; reference 
  52  ). However, these approaches also failed to reconstitute 
Th17 development and autoimmune myocarditis in IL-6      /      
mice (unpublished data), indicating that local availability, 
concentration, and/or half-life of exogenous and ectopically 
produced IL-6 are not suffi   cient to reconstitute endogenous 
IL-6 levels required for disease development. In addition, 
restoration of Th17 cells and autoimmunity in GM-CSF      /      
mice may require supplementation of both IL-6 and IL-23, as 
indicated by our results. 
  Although we cannot exclude that other antiapoptotic cyto-
kines stimulated by GM-CSF show a similar eff  ect than IL-6 
for T cell survival, we have shown that addition of IL-1 or 
IL-2 could not restore expansion of GM-CSF      /      CD4  +   
T cells. Although GM-CSF production by activated T cells can 
contribute to T cell proliferation in vitro, particularly when 
no other GM-CSF  –  producing cell is present in the micro-
environment (  Figs. 4 B and 6 C  ), our in vivo adoptive trans-
fer experiments with TCR tg CD4  +   T cells demonstrate that 
GM-CSF production by non  –  T cells is critical for survival of 
antigen-specifi  c CD4  +   T cells (  Fig. 5 F  ). Indeed, we found that 
a gemisch of Macrophages and DC isolated from WT mice at 
day 7 after myhc      614-629  /CFA immunization produced GM-
CSF (unpublished data). Interestingly, although CD11c  +   DC 
isolated from naive WT BALB/c mice and BM-DC did not 
    Figure 8.         Model for GM-CSF  –  mediated autoimmunity.   PAMPs  such 
as CpG and mycobacterial components in CFA induce DC activation/mat-
uration and production of proinfl  ammatory cytokines, including IL-6, 
which promote activation of naive CD4 T cells (Thp) and secretion of GM-
CSF, IFN-    , and IL-17. Macrophages (and possibly subpopulations of DC) 
can produce GM-CSF directly upon encounter of PAMPs. GM-CSF further 
enhances IL-6 and IL-23 production by DC and macrophages. IL-6 acts at 
two levels on activated T cells. It enhances survival (both Th1 and Th17) 
and, together with TGF-    , drives ROR    t expression to allow further Th17 
polarization. IL-23 can promote Th17 cell maintenance and/or patho-
genicity. Blue and red arrows indicate secretion of and stimulation 
of,  respectively.   
in GM-CSF      /      mice by ELISPOT assay (  Fig. 7 C  ). It is tempt-
ing to speculate that a majority of IFN-      –  positive cells co-
produce IL-17, as indicated by fl  owcytometry results of 
T cell transfer studies (  Fig. 7 A  ). These data indicate that GM-
CSF is critical for induction of IL-17 rather than IFN-     pro-
duction by CD4  +   T cells, but it later becomes essential for 
survival of both IL-17  –   and IFN-      –  producing cells in auto-
immune disease. 
    DISCUSSION   
  In this manuscript, we provide data suggesting that GM-CSF 
is essential for development of autoimmune myocarditis by 
promoting IL-6  –  dependent IL-17 production and survival of 
autoimmune CD4  +   T cells. GM-CSF      /      mice were almost 
completely protected from myocarditis induced by immuni-
zation of heart autoantigen (myhc      614-629  ), which is in agree-
ment with other publications reporting reduced EAE, arthritis, 
and gastritis in GM-CSF      /      mice (  22  –  24, 37  ) and suggests 
that GM-CSF plays a key role in development of organ-
related autoimmunity similar to IL-1, IL-6, and IL-23. Al-
though activated DC are among the main producers of the 
latter proinfl  ammatory cytokines, DC do not produce GM-
CSF. Consistently, injection of TLR- and CD40-activated 
BM-DC from WT mice, which can restore EAM in IL-
1R1      /      mice (  26  ), failed to restore full-blown EAM in GM-
CSF      /      mice. Nevertheless, injection of activated DC from 
WT or GM-CSF      /      mice increased disease severity in GM-
CSF      /     , mice although not to levels observed in WT mice. 
These data suggest that GM-CSF produced by other cells is 
important for DC activation in addition to TLR and CD40 JEM VOL. 205, September 29, 2008 
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  Our results do not exclude a role for GM-CSF in the 
eff  ector phase of the response. Elegant studies have demon-
strated previously that GM-CSF production by encepha-
litogenic T cells is required for the development of EAE, 
probably by activation of microglial cells (  23, 55, 56  ). Simi-
larly, GM-CSF produced by myosin-specifi  c eff  ector CD4  +   
T cells may activate heart-resident macrophages. Indeed, 
GM-CSF mRNA is up-regulated in the heart of rats with 
autoimmune myocarditis (  57  ), and we found that a high fre-
quency of CD4  +   T cells activated in vitro under Th17-polar-
izing conditions or CD4  +   T cells isolated from the CNS of 
mice with EAE coexpress GM-CSF and IL-17 (unpublished 
data), demonstrating that GM-CSF is an eff  ector cytokine of 
Th17 cells. 
  In summary, our studies demonstrate a previously unrec-
ognized role of GM-CSF in survival of Th17 cells that medi-
ate autoimmunity. GM-CSF regulates autoantigen-specifi  c 
CD4  +   T cells indirectly through stimulation of IL-6 and IL-
23 production by DC and macrophages in the presence of 
microbial products, as illustrated in the scheme shown in   Fig. 8  .   
Our results may have important implications for understand-
ing the mechanisms of cancer and other immunotherapies 
using GM-CSF as potent adjuvant. 
  MATERIALS AND METHODS 
  Mice.     GM-CSF      /      mice (provided by A. Dunn, Ludwig Institute for Can-
cer Research, Royal Melbourne Hospital, Victoria, Australia) (  21  ) were 
backcrossed to BALB/c for seven generations. DO11.10 transgenic GM-
CSF      /      mice were obtained by crossing DO11.10 mice (  58  ) with GM-
CSF      /      mice. BALB/c WT controls were purchased from Charles River 
Laboratories. Mice were maintained in isolated ventilated cages in an animal 
facility free of specifi  c pathogens (BioSupport) and were used for experi-
ments at the age of 8  –  12 wk. All animal experiments were performed in ac-
cordance with Swiss federal legislation and have been approved by the local 
overseeing body Gesundheitsdirektion Kanton Z  ü  rich, Veterinaeramt (per-
mission 148/2005). 
  Antibodies and cytokines.     Antibodies specifi  c to CD11c, CD86, CD40, 
CD4, IL-12p40, TNF-    , IFN-    , IL-17, or Annexin V, conjugated with 
FITC, PE, or APC were purchased from eBioscience. Anti-KJ1.26 mAb 
(idiotype-specifi  c DO11.10 TCR) was produced in house and conjugated 
with biotin. Purifi  cation of CD4  +   and CD11c  +   cells with magnetic beads 
(MACS; Miltenyi Biotec) was performed according to manufacturer instruc-
tions. Intracellular staining for cytokines was performed after fi  xation with 
2% formaldehyde in the presence of 0.5% saponin. Recombinant GM-CSF 
(PeproTech), IL-1     (provided by G. Spohn, Cytos Biotechnology, 
Schlieren, Switzerland), and hIL-6 (provided by L. Aarden, University of 
Amsterdam, Amsterdam, Netherlands) were used at concentrations indicated 
in the text. 
  Induction of EAM.     Mice were injected s.c. with 100   μ  g per mouse of the 
mouse cardiac myhc peptide myhc  614-629   Ac-RSLKLMATLFSTYASADR-
OH (ANAWA) emulsifi  ed in CFA (1 mg/ml H37Ra; DIFCO) on days 0 
and 7. At day 0, 400 ng per mouse of Pertussis Toxin (List Biological Labo-
ratories, Inc.) dissolved in PBS containing 1% normal mouse serum was in-
jected i.p. Mice were killed 21 d after the fi  rst injection. 
  Histopathology.     Immunized mice were killed and hearts were removed 
and fi  xed in 4% formalin (Sigma-Aldrich). Upon hemotoxylin and eosin 
staining, myocarditis was histologically scored using grades from 0 to 4 (0, no 
infl  ammatory infi  ltrates; 1, small foci of infl  ammatory cells between myocytes; 2, 
produce GM-CSF upon TLR stimulation (i.e., CpG, LPS) 
or in cocultures with CD4 T cells (  Figs. 2 and 4  ), we could 
measure GM-CSF in supernatants of CD11c  +   cells purifi  ed 
from immunized mice, although less than in the gemisch of 
macrophages and DC (not depicted). It is tempting to specu-
late that blood circulating infl  ammatory monocytes (CX-
3CR1  low  Gr1  +  ), which diff  erentiate into functional DC in 
infl  amed tissues (  53  ), have the ability to produce GM-CSF. 
  The absence of GM-CSF receptor on naive and eff  ector 
CD4 T cell subsets excludes direct regulation of Th17 lineage 
commitment by GM-CSF. Consistently, addition of GM-CSF 
to DC/CD4 T cell cocultures did not induce Th17 diff  eren-
tiation in vitro. However, stimulation of DC with microbial 
ligands or immunization with CFA adjuvants promoted DC 
IL-6 production (  Fig. 2, B and C  ; and   Fig. 3, A  –  C  ), resulting in 
GM-CSF production by activated CD4  +   T cells, which was 
required for Th17 polarization (  Fig. 4, E and F  ). Require-
ment of GM-CSF for Th17 development was overcome in 
the presence of TGF    /IL-6 or TGF    /IL-21, further indicat-
ing that GM-CSF acts indirectly by enhancing production of 
Th17-polarizing cytokines. 
  Consistent with a key role of IL-6 and IL-23 in genera-
tion and maintenance of Th17 cells, we found that impaired 
IL-6 and IL-23 production was associated with reduced 
numbers of Th17 cells in immunized GM-CSF      /      mice in 
vivo. Interestingly, numbers of IFN-      –  producing cells de-
termined by ELISPOT were also strongly reduced in GM-
CSF      /      mice immunized with myhc      614-629  /CFA, whereas 
development of IFN-      +  IL-17        (Th1) cells was unaff  ected in 
GM-CSF      /      mice after adoptive transfer of DO11.10 trans-
genic T cells and immunization with OVA/CFA. In con-
trast, a population of IFN-      +  IL-17  +   double producers was 
also reduced in this setting. Unfortunately, we could not dis-
tinguish IFN-      +  IL-17        and IFN-      +  IL-17  +   cells specifi  c for 
myhc      614-629   by ELISPOT, and it is possible that the major-
ity of IFN-      –  producing cells actually represent IFN-      +  IL-
17  +   double producers. The dynamics of IL-17 and IFN-     
production during diff  erentiation of distinct subpopulations 
depends on the number of antigen-specifi  c CD4  +   T cells and 
the strengths of TCR stimulation (unpublished data), which 
may also explain possible diff  erences in adoptive transfer of 
OVA  323-339  -specifi  c CD4  +   T cells and development of endog-
enous CD4  +   T cells specifi  c for myhc      614-629  . 
  The balance of Th17 and Treg cells is key for develop-
ment of autoimmunity. Development of Foxp3  +   Treg cells is 
enhanced at the expense of Th17 cells in IL-6  –  defi  cient mice 
immunized with the encephalitogenic peptide MOG  35-55  , 
which prevents development of EAE (  54  ). It is important to 
note that we did not fi  nd signifi  cant diff  erences in Foxp3  +   Treg 
cells in immunized GM-CSF      /      mice (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20071119/DC1), 
which may indicate that IL-6 levels in GM-CSF      /      mice are 
suffi   cient to balance development of Treg cells. However, it 
remains to be shown whether Treg number and function are 
similar in autoimmune myocarditis and EAE and the diff  er-
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day later, mice were bled and cells stained with KJ1-26 mAb to confi  rm 
comparable number of transgenic T cells. Transferred mice were immunized 
with 200   μ  g OVA  323-339   (ISQAVHAAHAEINEAGR; EMC Microcollec-
tion) in CFA (DIFCO). At days 3 and 5 after immunization, proliferation of 
T cells was analyzed by staining LN cells and FACS analysis. 
  For induction of Th17 cells in vivo, mice were boosted at day 7. Drain-
ing LN were isolated at day 14 and cells were stimulated with 10      7   M PMA 
and 10      6   M Ionomycin for 5 h. Brefeldin A (Sigma-Aldrich) was added for 
the last 2 h of activation. Cytokine expression was detected by intracellular 
staining as described in the previous section. 
  IL-6 supplementation by minipumps.     T cells were isolated from the 
spleen of DO11.10, purifi  ed, and transferred in GM-CSF  +/+   or GM-CSF      /      
mice as described in the previous section. After 1  –  2 d, osmotic minipumps 
(Alzet 2001; DURECT Corporation) were fi  lled with 26   μ  g (3   μ  g/d deliv-
ery) rec hIL-6 and s.c. implanted in mice. Shortly after implantation, mice 
were immunized s.c. with 200   μ  g OVA  323-339   emulsifi  ed in CFA. 
  Quantitative PCR.     Cells used to quantify cytokine receptors were FACS 
sorted (FACS Aria; Becton Dickinson). All cell populations were   >  99% pure. 
After in vitro culture in polarizing conditions for 3 d, cDNA was extracted 
with Tri-reagent (Molecular Research Center) according to the manufactur-
er  ’  s instructions. Quantitative PCR was performed on an iCycler (Bio-Rad 
Laboratories) according to the manufacturer  ’  s instructions. Oligonucleotides 
used for PCR amplifi  cation of cytokines and receptors were the following: 
GM-CSFR-     forward, ACGTCATGCACCGTGACC; GM-CSFR-     re-
verse, CATTGACATCCAGCGTGA; AIC2B forward, ACCAGCAAATG-
GCACTCAC; AIC2B reverse, GCTGGTGATAGAGGGTCATGT; CD122 
forward, GAAGAGGCTCTGAATGTCACAA; CD122 reverse, ACGAC-
CCGAGGATCAGGTT; IL17 forward, GCAAAAGTGAGCTCCAGA-
AGG; IL17 reverse, AGCTTCCCAGATCACAGAGG; IFN-     forward, 
GCTCTGAGACAATGAACGCTAC; and IFN-     reverse, TTCTAGGCT-
TTCAATGACTGTGC. 
  ELISPOT.     Filter plates (96-well; Multi-Screen-IP; Millipore) were coated 
overnight at 4  °  C with 2   μ  g/well of affi   nity chromatography  –  purifi  ed anti  –
  IFN-     (mAB AN18,) or with 0.1   μ  g/well of anti  –  IL-17 (BD Biosciences) in 
PBS. Plates were washed twice with PBS and blocked with IMDM/10% 
FCS for 2 h at RT (200   μ  l/well). 10  6  /ml BALB/c BM-DC was pulsed with 
10   μ  g myhc  614-629  /ml for 15 min on ice. DC were adjusted to 0.4   ×   10  6  /ml, 
and 20,000 cells were used as APC. 10  5   purifi  ed CD4  +   T cells were incu-
bated 6 h together with peptide-pulsed or unpulsed APCs at 37  °  C. Setups 
with 10  5   T cells only and CD4  +   T cells stimulated with 2.5   ×   10      7   M PMA 
and 1.25   μ  g/ml ionomycin (Sigma-Aldrich) served as controls. Plates were 
washed fi  ve times with PBS, and 2   μ  g/ml anti  –  IFN-        biotin (mAb 
XMGD6) or 2   μ  g/ml anti  –  IL-17 (BD Biosciences) were added to the re-
spective plate and incubated for 1 h at room temperature. Plates were washed 
fi  ve times with PBS and incubated for 1 h with streptavidin-alkaline-phos-
phatase (1:1,000 in PBS; Dianova). After fi  ve further washing steps, the spots 
were visualized by using the BCIP/NBT (5-bromo-4-chloro-3-indol-phos-
phate-toluidine/nitroblue-tetrazoliumchloride) Plus substrate (Mabtech). 
The enzymatic reaction was stopped by rinsing the wells with water. Plates 
were counted with an ELISPOT Reader (Autoimmun Diagnostika GmbH). 
ELISPOT responses of individual mice are expressed as mean number of 
specifi  c spot-forming cells (experimental sample, negative control with un-
pulsed APCs) per 100,000 CD4  +   T cells from triplicate measurements. 
  Statistical analysis.     Statistical analysis was performed with the help of 
Prism (GraphPad Software, Inc.). Two-tailed unpaired Student  ’  s   t   test with 
a confi  dence interval of 95% was performed for normal distributed data. 
Histological scores were analyzed with two-tailed Mann-Whitney test. Results 
obtained by fl  ow cytometry in   Fig. 7 A   were evaluated using Kolmogorov-
Smirnov statistical analysis for comparisons between frequency distributions. 
If not mentioned otherwise, error bars indicate SD. P   <   0.05 was considered 
to be signifi  cant. 
larger foci of   >  100 infl  ammatory cells; 3,   >  10% of a cross section involved; 
4,   >  30% of a cross section involved). 
  ELISA antibody measurement.     ELISA against myhc  614-629   was performed 
as previously described (  28  ). In brief, coating of MaxiSorp microtiter plates 
(Thermo Fisher Scientifi  c) with 5   μ  g/ml streptavidin (Invitrogen) was fol-
lowed by incubation with biotinylated myhc  614-629   (ANAWA). Afterward, 
threefold serial dilutions of serum were incubated for 1 h at room tempera-
ture, followed by extensive washing and the addition of Alkaline-phospha-
tase  –  labeled anti  –  mouse IgG (SouthernBiotech). After development with 
  p  -nitrophenylphosphate (Sigma-Aldrich), antibody titers were determined at 
half maximal OD  405nm  . 
  DC activation.     Spleens of mice were digested for 1 h with collagenase and 
purifi  ed by MACS using anti-CD11c magnetic beads (Miltenyi Biotec). Af-
terward, DC were activated with the following diff  erent stimuli: 1   μ  g/ml 
LPS (Sigma-Aldrich) or titrating amounts of CpG (Microsynth). For surface 
staining, DC were incubated at 37  °  C with 5% CO  2   for 12 h. Afterward, cells 
were blocked with anti-CD16/CD32 (eBioscience) and stained for activa-
tion markers. Cytokine ELISAs were performed on supernatants from DC 
culture stimulated for 24 h. 
  Cytokine production.     IL-6 and IL-12p70 levels were measured by ELISA. 
Microtiter plates (MaxiSorp) were coated with unlabeled capture anti  –  IL-6 
or anti  –  IL-12p40 antibodies (eBioscience) at a concentration of 2   μ  g/ml for 
12 h at 4  °  C. After blocking the plates with 1% BSA and washing, samples 
were incubated on the plates for 1 h. Detection was performed by incubating 
the plates with 1   μ  g/ml biotinylated anti-IL6 or anti-IL12p70 antibodies, re-
spectively (eBioscience), followed by alkaline-phosphatase  –  labeled streptavi-
din (SouthernBiotech). Absorption at 405 nm was measured after incubation 
of the plates with   p  -nitrophenylphosphate. 
  In vitro proliferation assay.     Spleens of mice were digested for 1 h with 
collagenase and purifi  ed by MACS using anti-CD11c magnetic beads (Milt-
enyi Biotec), essentially as previously described (  34  ). CD4  +   T cells from 
DO11.10 tg GM-CSF      /      or GM-SF  +/+   mice were isolated by MACS using 
anti-CD4 magnetic beads. 10  5   CD4  +   T cells from tg mice were cultured 
with 2   ×   10  4   DC or 10  5  mitomycine C  –  inactivated splenocytes and titrating 
concentrations of OVA  323-339   (EMC Microcollections) or ovalbumin protein 
(grade V; Sigma-Aldrich). In experiments indicated, cultures were supple-
mented with 20 ng/ml IL-1    , IL-2 (1:500 dilution of a supernatant of a hy-
bridoma producing hIL-2), and 20 ng/ml hIL-6. Proliferation was measured 
by pulsing cultures with   3  H-Thymidine (Hartmann Analytic) for the last 12 h 
of a 3-d culture. Proliferation index was calculated by dividing the cpm at 
200 nM OVA  323-339   by cpm at baseline (without antigen). 
  Antigen-specifi  c Th1 and Th2 polarization in vitro.     Spleens of mice 
were digested for 1 h with collagenase, and DC was isolated by an OptiPrep 
gradient (Axis-Shield), followed by sorting of CD11c  +   cells on a FACS Van-
tage (BD Biosciences) to a purity   >  95%. For Th1 and Th2 polarization, 
naive CD4  +   CD62L  high   T cells from spleens of DO11.10/GM-CSF  +/+   or 
DO11.10/GM-CSF      /      mice were isolated by MACS using anti-CD4 mag-
netic beads followed by sorting CD62L  high   cells, using FACS Vantage, to a 
purity   >  98%. 10  4  DC and 5   ×   10  4   naive CD4  +   T cells were cocultured in the 
presence of high (1 mM), intermediate (100   μ  M) or low (10   μ  M) concentra-
tions of ovalbumin protein (grade V) for 3 d before addition of 10  4   DC and 
the same concentrations of antigen for another 2 d. T cell activation was as-
sessed by staining with anti-CD25 mAb and CD62L mAb at day 3 of cocul-
ture. Th1/Th2 polarization was analyzed at day 5 by intracellular staining of 
IL-4 and IFN-     as previously described (  34  ). 
  Visualization of CD4 T cell expansion and subset diff  erentiation 
in vivo.     T cells were isolated from the spleen of DO11.10 GM-CSF  +/+   or 
DO11.10/GM-CSF      /      mice by sorting with anti-CD4 magnetic beads. Af-
ter labeling of purifi  ed CD4  +   T cells with CFSE (Invitrogen), 5   ×   10  6   cells 
per mouse were injected intravenously in WT or GM-CSF      /      mice. One JEM VOL. 205, September 29, 2008 
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